FDA 483 responses: what the new draft guidance means for you
⚠️ 483 responses are under new scrutiny.
With the FDA’s latest draft guidance, fixing observations isn’t enough—you need to show full control of your quality system.
Join this free session with Antiksha Joshi, Pharma QMS Consultant, to learn what’s changing, how inspectors assess responses, and how to build CAPAs that hold up.
With the FDA’s new draft guidance on responding to Form 483 observations, expectations are shifting.
What used to be “acceptable” responses may no longer hold up.
In this session, we’ll unpack what these changes really mean in practice and how to prevent quality issues in the first place.
We’ll explore:
- What the new FDA draft guidance on 483 responses actually expects from you
- How to approach audits with a clearer understanding of the inspector’s mindset
- The systemic gaps that commonly lead to repeat observations
- Practical strategies to strengthen your responses and stay compliant
- How to drive management engagement and build stronger CAPAs
You’ll hear from Antiksha Joshi, Pharmaceutical QMS Consultant and Angel Buendía, Scilife’s Knowledge Manager, will be moderating this online session.
📅 April 28th, 2026 | 11:00H (CEST)
It’s not just about responding to observations but building a more robust quality system!